Let us know who you are and what innovation & entrepreneurship programs, services or information you are interested in.Go
We give Pitt Innovators the opportunity to consult with legal and early-stage investor professionals at no cost. These 30 minute…Learn More
Innovation Igniter is a 2-hr workshop designed to provide those who are curious about advancing an innovation or idea towards licensing or…Learn More
The Randall Family Big Idea Competition is an experience-based learning opportunity for Pitt students with big ideas. Discover how to…Learn More
The Pitt Ventures First Gear program helps shape Pitt inventions originating from University research from early-stage discoveries into products and…Learn More
Fourth Gear program offers an opportunity for early-stage small businesses in the region to obtain hands-on guidance and mentorship, taking…Learn More
The Innovation Igniter program is designed to help participants get introduced to the commercialization process and path to licensing their…Learn More
The Innovation Institute has partnered with the largest seed stage investor in Southwestern PA, Innovation Works. Attend this rare opportunity to…Learn More
Most financing options require a solid business plan. Learn all you need to know about operational and production planning, conducting…Learn More
Learn about profit vs. non-profit entities, hybrids and alternative legal models.Learn More
Cumulative startups since 1996
Invention Disclosures received*
U.S. Patents issued*
Media Release HiberSense Wins $10K in AUTM Venture Challenge AUSTIN, Texas - February 14, 2019 — HiberSense, Inc., a start-up from the University of Pittsburgh Innovation Institute, has won the…
Grants to support applied technology projects in the early stages of development with “kickstart” funding toward the goal of transitioning to clinical adoption.
Koutif Therapeutics, which licensed patents from Pitt and the U.S. Department of Veterans Affairs, is pursuing a Phase I clinical trial of an investigational new drug targeted to diseases such as ulcerative colitis and Chrohn's Disease.
Research at Pitt demonstrated potential effectiveness of INmune's therapy in drug-resistant melanoma, currently in Phase I trials.